Kamada’s shares fell 6.8% after earnings, reflecting investor disappointment with an acknowledged shipment delay that contributed to first-quarter revenue and adjusted EBITDA coming in only in line with expectations rather than showing growth momentum. Despite management's reiteration of full-year guidance and confidence in demand, the market appears skeptical of the outlook given early execution challenges.

• Reported Q1 revenues and adjusted EBITDA were in line with expectations, not exceeding them, impacted by a temporary shipment delay of a single order.
• Management reaffirmed 2026 annual guidance of $200-$205 million in revenue and $50-$53 million in adjusted EBITDA, targeting double-digit growth solely through organic initiatives.
• Underlying product demand, including increases in U.S. and international sales of key products like KEDRAB and GLASSIA, was highlighted but without clear evidence of acceleration in the quarter.
• Expansion plans include launching additional biosimilars in Israel and growing plasma collection operations to improve vertical integration and cost control.
• Ongoing clinical studies for CYTOGAM and increased market demand for VARIZIG support longer-term growth but have yet to translate into near-term financial upside.